Free Trial

Galecto (GLTO) Competitors

Galecto logo
$3.48 +0.09 (+2.50%)
Closing price 03:45 PM Eastern
Extended Trading
$3.48 0.00 (0.00%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GLTO vs. QTTB, LPCN, CING, MTEX, GELS, CARM, MRKR, CTXR, RVPH, and PMN

Should you be buying Galecto stock or one of its competitors? The main competitors of Galecto include Q32 Bio (QTTB), Lipocine (LPCN), Cingulate (CING), Mannatech (MTEX), Gelteq (GELS), Carisma Therapeutics (CARM), Marker Therapeutics (MRKR), Citius Pharmaceuticals (CTXR), Reviva Pharmaceuticals (RVPH), and Promis Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry.

Galecto vs. Its Competitors

Q32 Bio (NASDAQ:QTTB) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Galecto has lower revenue, but higher earnings than Q32 Bio. Q32 Bio is trading at a lower price-to-earnings ratio than Galecto, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Q32 Bio$1.16M34.92-$47.73M-$4.94-0.67
GalectoN/AN/A-$21.44M-$15.53-0.22

In the previous week, Galecto had 3 more articles in the media than Q32 Bio. MarketBeat recorded 4 mentions for Galecto and 1 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 0.00 beat Galecto's score of -0.67 indicating that Q32 Bio is being referred to more favorably in the media.

Company Overall Sentiment
Q32 Bio Neutral
Galecto Negative

Q32 Bio has a beta of -0.07, meaning that its stock price is 107% less volatile than the S&P 500. Comparatively, Galecto has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500.

Q32 Bio presently has a consensus price target of $12.17, indicating a potential upside of 266.47%. Galecto has a consensus price target of $10.00, indicating a potential upside of 186.94%. Given Q32 Bio's higher possible upside, analysts clearly believe Q32 Bio is more favorable than Galecto.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Q32 Bio
0 Sell rating(s)
6 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Galecto
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 14.2% of Galecto shares are held by institutional investors. 40.0% of Q32 Bio shares are held by insiders. Comparatively, 10.8% of Galecto shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Galecto's return on equity of -98.27% beat Q32 Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Q32 BioN/A -447.33% -59.77%
Galecto N/A -98.27%-84.29%

Summary

Q32 Bio beats Galecto on 8 of the 14 factors compared between the two stocks.

Get Galecto News Delivered to You Automatically

Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GLTO vs. The Competition

MetricGalectoMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.50M$2.96B$5.56B$9.04B
Dividend YieldN/A2.42%5.25%4.03%
P/E Ratio-0.2221.1127.1820.14
Price / SalesN/A284.26439.56137.26
Price / CashN/A42.7337.5058.41
Price / Book0.327.748.085.60
Net Income-$21.44M-$54.96M$3.16B$248.43M
7 Day Performance1.01%6.04%3.77%5.15%
1 Month Performance3.72%4.47%3.90%7.62%
1 Year Performance-72.18%6.12%34.22%21.56%

Galecto Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GLTO
Galecto
3.2497 of 5 stars
$3.49
+2.5%
$10.00
+186.9%
-73.1%$4.50MN/A-0.2240News Coverage
Gap Down
QTTB
Q32 Bio
2.2529 of 5 stars
$1.49
+2.8%
$12.17
+716.6%
-92.6%$17.69M$1.16M-0.3039Gap Up
LPCN
Lipocine
1.6298 of 5 stars
$3.16
-4.0%
$9.00
+184.8%
-58.4%$17.60M$11.20M-3.1010
CING
Cingulate
2.991 of 5 stars
$4.07
+0.5%
$26.00
+538.8%
+1,116.8%$17.19MN/A-0.4820News Coverage
MTEX
Mannatech
0.3099 of 5 stars
$9.35
+3.9%
N/A+18.8%$17.11M$117.87M-93.50250High Trading Volume
GELS
Gelteq
N/A$1.73
-4.4%
N/AN/A$17.08M$100K0.00N/AGap Up
CARM
Carisma Therapeutics
2.4295 of 5 stars
$0.39
-2.2%
$1.93
+391.6%
-64.8%$16.74M$19.63M-0.2520Gap Up
MRKR
Marker Therapeutics
3.7017 of 5 stars
$1.53
+4.8%
$13.17
+760.6%
-63.4%$16.52M$6.59M-1.1560
CTXR
Citius Pharmaceuticals
2.4427 of 5 stars
$1.59
+3.9%
$53.00
+3,233.3%
-89.5%$16.27MN/A0.0020Gap Down
High Trading Volume
RVPH
Reviva Pharmaceuticals
2.4706 of 5 stars
$0.38
+12.9%
$9.00
+2,261.6%
-67.5%$16.20MN/A-0.485Gap Up
High Trading Volume
PMN
Promis Neurosciences
2.8343 of 5 stars
$0.48
+0.7%
$4.50
+830.1%
-82.4%$15.70MN/A-9.685Gap Up

Related Companies and Tools


This page (NASDAQ:GLTO) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners